Janssen disappointed with second NICE no for Spravato
NICE has concerns with the evidence submitted but Janssen insists the nasal spray is a cost-effective use of NHS resources
Read More
Tag: nasal spray
New data highlights value of Janssen’s Spravato
The approval of the drug is a new way of treating adults with TRD that is unlike other treatment options in psychiatry.
Read More
Janssen files nasal spray for depression
Janssen has submitted a marketing application to the European Medicines Agency (EMA) seeking approval of investigational nasal spray esketamine for the treatment of major depressive disorder.
Read More
Phase III success for Janssen’s esketamine in treatment-resistant depression
Janssen has presented data from pivotal Phase III clinical studies backing use of esketamine spray in treatment-resistant depression.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
